The HHS wants to move oversight of the controversial drug discount program to the CMS, which has a more aggressive history ...

Oklahoma lawmakers passed HB 2048 to protect the 340B Drug Pricing Program, overriding a veto amid growing pressure from pharmaceutical interests.

A federal judge has rejected Johnson & Johnson’s challenge to block its proposed rebate model under the 340B Drug Pricing Program, Bloomberg Law reported June 27. Judge Rudolph Contreras of the U.S.

Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...

Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In preclinical testing, KT-485 demonstrated ...

Under the federal 340B program, in order to have a drug qualify for coverage by Medicaid and Medicare Part B, drug manufacturers must enter a pharmaceutical pricing agreement that discounts the ...

Dive Brief: Kymera Therapeutics and Gilead Sciences will develop oral molecular glue degraders under a deal announced Wednesday, which could hand the former as much as $85 million in upfront and ...

Gusacitinib was acquired by Formation Bio in late 2022 from Asana BioSciences as part of a broader portfolio of investigational medicines. This transaction with Sanofi ushers gusacitinib into its next ...

But as the program, known as 340B, has grown, drug makers have pushed back at what they see as exploitation of the system, particularly by pharmacies and pharmacy benefit managers, and have begun ...

Overview SNY Sanofi SA $48.23 -0.14 % The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals Inc. REGN -2.10% ...

BOSTON, 19th June, 2025 (WAM) -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, has signed a Memorandum of Understanding (MoU) with Sanofi, a ...

Bon Secours Mercy Health didn’t respond to requests for comment. But observers said such conduct is likely happening elsewhere in the 50-hospital chain. Explosive growth Intended to subsidize care for ...